Keke Palmer shared her personal struggle with premenstrual dysphoric disorder (PMDD) at the 3rd annual Women's Health Lab in New York City, describing symptoms so severe they became unbearable. Despite the intensity of her experience, Palmer faced significant delays in obtaining an accurate diagnosis, a challenge that reflects a broader healthcare gap affecting many menstruating individuals.
PMDD is a severe form of premenstrual syndrome that causes extreme mood swings, depression, anxiety, and fatigue in the luteal phase of the menstrual cycle. Unlike standard PMS, PMDD substantially impairs functioning and quality of life. The condition affects an estimated 5 to 8 percent of menstruating people, yet diagnosis remains elusive for countless patients.
Palmer's experience mirrors a documented pattern in women's health research. Diagnostic delays occur because PMDD symptoms mimic other psychiatric conditions, and many healthcare providers lack familiarity with the disorder. Patients often receive diagnoses of depression or anxiety disorders first, delaying appropriate treatment. The Diagnostic and Statistical Manual of Mental Disorders (DSM-5) formally recognizes PMDD, yet many primary care physicians do not routinely screen for it.
Treatment options exist once diagnosis occurs. The FDA-approved selective serotonin reuptake inhibitors (SSRIs) such as sertraline and fluoxetine effectively reduce PMDD symptoms in 60 percent of users when dosed during the luteal phase only. Lifestyle modifications including exercise, dietary changes, and stress management provide additional support.
Palmer's public discussion serves an important function in raising awareness. When high-profile individuals share experiences with underdiagnosed conditions, healthcare-seeking behavior increases and stigma decreases. Her openness encourages others experiencing similar symptoms to advocate for proper evaluation rather than accepting dismissive explanations.
Medical professionals recommend tracking